Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydroxyurea Added to Efavirenz, Didanosine, and Stavudine in HIV-Infected Patients
NCT00002230Phase 3Completed
- Sponsor
- Northwestern University
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Hydroxyurea + ART with Placebo + ART (2 arms). Primary endpoints: Viral parameters (e.g., HIV RNA levels) at 48 weeks, Immunologic parameters (e.g., CD4 cell count) at 48 weeks and 1 more. Status: completed.
02
Drugs
hydroxyurea
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00002230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002230.